To customize how your Tropy item is mapped to CSL/JSON and Zotero, duplicate your Tropy template in Tropy's template editor and assign each field you want to export a CSL/JSON field by setting the ...

Abstract: Intelligent reflecting surface (IRS) is an enabling technology to engineer the radio signal propagation in wireless networks. By smartly tuning the signal reflection via a large number of ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

One day after CSL suddenly replaced its CEO, the company provided dismal financial figures that helped explain why. In its half-year report, CSL said its net profit plummeted (PDF) from $2 billion in ...

CSL ’s interim 2026 underlying EBIT fell 3% on 5% lower plasma sales. Full-year guidance of mid-single-digit earnings growth was reaffirmed, and the Seqirus and Vifor divisions fared relatively well.

CSL’s share slump following weak profits and a sudden CEO exit has pulled Australian healthcare stocks to multi-year lows, highlighting sector-wide concerns over regulation and investor sentiment. CSL ...

The worst US flu season in decades did not shield one of Australia’s largest companies, biotechnology firm CSL, from another brutal market response as vaccine scepticism from Trump administration ...

Having birched CSL shares by 5% yesterday, investors reacted by wiping a further 12% from the value of the stock. In total, that’s $16 billion of market cap, with CSL shares now at their lowest level ...

CSL (ASX: CSL) opened 9% lower on Wednesday to its lowest level since May 2018 after reporting a weaker-than-expected half-year result. The selloff follows a poorly timed announcement on Tuesday at ...

Earnings call CSL reported H1 FY26 revenue of $8.3B (down 4% YoY, constant currency) and NPATA of $1.9B (down 7%). Reported NPAT fell 81% due to $1.05B in impairments. Despite challenges, full-year ...

The global biotechnology company announced minutes before the market closed on Tuesday that Mr McKenzie would be immediately replaced by Gordon Naylor, a current CSL director who has held a number of ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...